Sara Razi is Global Co-Chair of the Firm’s Antitrust and Trade Regulation Practice. Sara’s practice focuses on merger reviews, government antitrust investigations, antitrust litigation, and counseling on a variety of competition issues. Sara joined Simpson Thacher in 2013 from the FTC, where she served in senior roles for nearly a decade.
Sara represents clients in antitrust investigations by the DOJ, FTC, and States and has secured successful outcomes in several complex and closely-watched mergers and high-profile antitrust litigations. Her extensive private-sector and government antitrust experience spans a multitude of industries including healthcare, pharmaceuticals, technology, supermarkets and other retailers, consumer products, financial services, media, and telecommunications.
Sara is recognized by The Legal 500 as a “Leading Lawyer” and by Chambers USA. Sources note she is “a very seasoned and knowledgeable antitrust attorney” who “has the unique ability to give very practical advice about how regulators would react to matters,” with “extensive knowledge of agency strategy.” Sara is also ranked in the “Top 250 Women in Litigation” by Euromoney’s Benchmark Litigation. In 2024, Sara was named “Antitrust Litigator of the Year” by Euromoney’s Benchmark Litigation, and in 2023, she was named a “MVP” in Competition/Antitrust by Law360; a Litigation “Trailblazer” by The National Law Journal; “Antitrust & Competition Lawyer of the Year” by Euromoney’s Women in Business Law Americas Awards; and among The Deal’s “Top Women in Dealmaking.” In 2025 she was again featured as one of Global Competition Review’s “Women in Antitrust” where she is separately described by GCR as one of the “best FTC merger advisers in the business.” Sara speaks frequently on antitrust issues at conferences sponsored by the ABA, law schools, and private organizations. She also serves as Co-Chair of the Firm’s Pro Bono Committee and as a member of the DC Legal Aid board of trustees.
Updated Oct 2025
Change Healthcare in its $13.8 billion acquisition by UnitedHealth Group, which won the Impact Case Award at Euromoney’s Benchmark Litigation Awards 2024, and was named “Merger Control Matter of the Year – Americas” at Global Competition Review’s GCR Awards 2023, after successfully defending a DOJ Antitrust Division litigation.
Mattress Firm in its $5 billion acquisition by Tempur Sealy International, successfully defending an FTC litigated challenge.
Amedisys in successfully resolving DOJ Antitrust Division litigation challenging its proposed $3.3 billion acquisition by UnitedHealth Group.
- PPD, Inc. in its $17.4 billion acquisition by Thermo Fisher Scientific.
- Competition/antitrust
- Government and regulatory
- Automotive
- Consumer goods and services
- Energy
- Financial services
- Food and beverage
- Healthcare
- Media
- Oil and gas
- Pharmaceutical and life sciences
- Technology and telecommunications
- Transport
- J.D., summa cum laude, Note and Comment Editor, American University Law Review - American University Washington College of Law - 2000
- B.A. in molecular, cellular & developmental biology - University of Colorado - 1995
- Board Member, Legal Aid Society of the District of Columbia
- District of Columbia - 2001
- Maryland - 2000